Unlike conventional Alzheimer's drugs that largely manage memory loss and behavioural symptoms, donanemab targets ...

Lilly launches Lormalzi, first and only once-monthly amyloid plaque-targeting therapy to treat early symptomatic Alzheimer’s disease in India: Our Bureau, Mumbai Wednesday, May ...

The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle ...

French and Canadian researchers have shown for the first time that mitochondrial dysfunction can directly cause cognitive ...

A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, ...

Alzheimer's Disease," Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell continue their ...

A new experimental Alzheimer’s compound called FLAV-27 improved memory and reduced disease-like damage in worms and mice.

Scientists in Japan found that arginine, a common amino acid already used in supplements and medicine, reduced harmful ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Something fishy may be going on with a daily pill trusted by millions of Americans. Across the country, older adults have ...

A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein may not lead to meaningful improvements for patients.

Scientists have discovered a way to help the brain clean itself of harmful Alzheimer’s plaques by activating its own support cells. By increasing a protein called Sox9, researchers were able to boost ...